Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Therapeutics Pain (PTIE) Stock Price

Business



[ad_1]

Bread Therapeutics logo "title =" Bread Therapeutics logo "clbad =" companylogo "/> Media coverage about Bread Therapeutics (NASDAQ: PTIE) has a positive edge on Saturday, Accern Sentiment reports. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Accern 's Scale Accords Accumulated Scale of 47.351174152384 out of 100, indicating that recent media coverage is unlikely to have an impact on the stock price </p> <p> These are some of the media stories that may have been effected Accern's scoring: </p> <p> Pain Therapeutics traded down $ 0.02, hitting $ 2.40, trading midday trading on Friday, Marketbeat Ratings reports. e stock had a trading volume of 87,293 shares, compared to its average volume of 452,766. The firm has a market cap of $ 16.76 million, a P / E ratio of -1.32 and a beta of 2.70. Pain Therapeutics has a month of $ 2.04 and a 12 month high of $ 12.80. </p> <p> Pain Therapeutics (NASDAQ: PTIE) last Wednesday, May 9th. The biopharmaceutical company reported ($ 0.33) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($ 0.66) by $ 0.33. equities badysts anticipate that Pain Therapeutics will post -1.65 EPS for the current year. </p> <p> A number of badysts have recently issued reports on the company. ValuEngine Raised Therapeutics from a "sell" rating to a "hold" rating in a research report on Wednesday, May 2nd. Zacks Investment Research Therapeutics Bread Therapy Therapeutics Bread Therapeutics Company Profile </strong> </p> <p> Bread Therapeutics, Inc. expands drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal bread patch for pain relief; PTI-125, a small molecule Alzheimer's disease; and PTI-125DX, ​​a blood-based diagnosis / biomarker to detect Alzheimer's disease. <!--ViewCount:ArticleHistoryID=21376496&PostDate=2018-7-14&type=m&id=481211--></p> <p style= Receive News & Reviews for Daily Pain Therapeutics </strong> – Enter Your email address to receive a daily summary of the latest news and badysts' ratings for Pain Therapeutics and related companies MarketBeat.com's FREE daily email newsletter. </p> <p><!-- End Footer Opt-In --></p></div> </pre> [ad_2] <br /><a href=Source link

Tags

Powered by https://naaju.com/ireland | Designed by Naaju
© Copyright 2024, All Rights Reserved